Durham, NC-based Bioventus is hoping to expand its position in the allograft market through a collaboration with LifeLink Foundation. The accord will have the companies work together to co-develop a next-generation bone allograft solution for use in spine and trauma surgery.
Bivoentus specializes in orthobiologic products for bone healing, bone graft, and knee osteoarthritis.
“LifeLink is a fully equipped tissue bank,” Samson Tom, vice president of research and development at Bioventus, told MD+DI. “Here at Bioventus, we have significant infrastructure, but we are not a tissue bank. We recognize partnering with a tissue bank provides broad capabilities and would be a significant advantage for us.”
The companies did not discuss financial terms of the collaboration.
“The gift of tissue donation is invaluable and offers the opportunity to benefit so many patients in need,” said Jean Davis, president and CEO of LifeLink Foundation. “Companies like Bioventus are helping to further enhance the immeasurable impact of tissue donations by investing in R&D to bring new solutions to the market and we are excited for our research teams to collaborate together on this development initiative.”
The first fruits of the collaborative effort could come in about two years.
“The first project that we’re working on will require a two-year-development timeline,” Tom said. “We’re also looking at the development of the technology as a platform. There might be other products that might result from this too.”
Lately, Bioventus has been raising its profile and keeping itself busy with trials and investments.
Late last year, the company spoke during BIOMEDevice San Jose 2017 about its plans to help drive patient compliance.
Earlier this year, Bioventus invested about $2.5 million in CartiHeal for the development of an ongoing clinical study of Agili-C, a device for treating joint surface lesions in traumatized and osteoarthritic knee joints.
Bioventus’s $2.5 million boost complemented CartiHeal’s latest financing round, led by aMoon, together with Johnson & Johnson Innovation, Peregrine Ventures, and Elron, bringing the total round to $21 million.
In September of last year, Bioventus said the first patients have been enrolled in its Bioventus Observational Non-interventional EXOGEN Studies (BONES) clinical development program.
The study includes three observational, non-interventional, direct-to-patient studies designed to collect real-world data on the use of the Exogen Ultrasound Bone Healing System. The device uses effective low-intensity and pulsed ultrasound to help stimulate the body’s natural bone healing process.